Live
- Shreyas Media secures exclusive advertising rights for ‘MahaKumbh Mela 2025’
- Experience the journey of art
- Seven iconic ghats undergo makeover for Mahakumbh
- Smog engulfs capital with ‘severe’ air quality
- Slur against HDK wrong, Zameer will be corrected: K’taka Cong
- Himalayan Echoes Literature Festival returns to Nainital with a focus on art, environment, and culture
- Taking Off: Solo travelling as a minor
- MVA will win over 160 seats, form govt in Maha: Shivakumar
- Athletes join forces to champion grassroots development at exclusive Sports For All conclave
- Farmers in Gadag protest against wind companies over land encroachment
DCGI okays Covovax as booster dose
DCGI has approved market authorisation to Covid-19 vaccine Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin, official sources said on Monday.
New Delhi: The Drug Controller General of India (DCGI) has approved market authorisation to Covid-19 vaccine Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin, official sources said on Monday.
The DCGI's approval came following recommendation by the Subject Expert Committee of the Central Drugs Standard Control Organisation (CDSCO). Prakash Kumar Singh, Director of Government and Regulatory Affairs at the Serum Institute of India (SII), had recently written to the DCGI for the approval of Covovax heterologous booster dose for those aged 18 years and above in view of the escalating Covid-19 pandemic situation in some countries, an official source had said.
The DCGI had approved Covovax for restricted use in emergency situations in adults on December 28, 2021, in the 12-17 age group on March 9, 2022, and in children aged 7-11 years on June 28 last year subject to certain conditions.
